Rasuvo Approval History
- FDA approved: Yes (First approved July 11th, 2014)
- Brand name: Rasuvo
- Generic name: methotrexate
- Dosage form: Injection
- Previous name: MPI-2505
- Company: Medac Pharma, Inc.
- Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis
Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.
Development History and FDA Approval Process for Rasuvo
|Jul 14, 2014||FDA Approves Rasuvo (methotrexate) Injection|
|Jan 27, 2014||Medac Pharma, Inc. Secures FDA Acceptance of a New Drug Application (NDA) for Methotrexate-Containing Autopen|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.